Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species

References

• Acosta EP, Limoli KL, Trinh L, et al. (2012). Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Ch 56:5938–45.
   PubMed Web of Science ®Google Scholar
• Alam C, Whyte-Allman SK, Omeragic A, Bendayan R. (2016). Role and modulation of drug transporters in HIV-1 therapy. Adv Drug Delivery Rev 103:121–43.
   PubMed Web of Science ®Google Scholar
• Ances BM, Ellis RJ. (2007). Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27:86–92.
   PubMed Web of Science ®Google Scholar
• Anderson KW, Mast N, Hudgens JW, et al. (2016). Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity. J Biol Chem 291:11876–86.
   PubMed Web of Science ®Google Scholar
• Avery LB, Sacktor N, McArthur JC, Hendrix CW. (2013). Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: Applying the law of mass action to predict protein-free drug concentration. Antimicrob Agents Ch 57:1409–14.
   PubMed Web of Science ®Google Scholar
• Barry JA, Robichaud G, Bokhart MT, et al. (2014). Mapping antiretroviral drugs in tissue by IR-MALDESI MSI coupled to the Q Exactive and comparison with LC-MS/MS SRM assay. J Am Soc Mass Spectr 25:2038–47.
   PubMed Web of Science ®Google Scholar
• Best BM, Koopmans PP, Letendre SL, CHARTER Group, et al. (2011). Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Ch 66:354–7.
   PubMed Web of Science ®Google Scholar
• Best BM, Letendre SL, Brigid E, CHARTER Group, et al. (2009). Low atazanavir concentrations in cerebrospinal fluid. AIDS 23:83–7.
   PubMed Web of Science ®Google Scholar
• Boffito M, Back DJ, Blaschke TF, et al. (2003). Protein binding in antiretroviral therapies. AIDS Res Human Retrovirus 19:825–35.
   PubMed Web of Science ®Google Scholar
• Bousquet L, Pruvost A, Didier N, et al. (2008). Emtricitabine: inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci 35:247–56.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Di Perri G, Bonora S. (2014). Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. Clin Pharmac 53:891–906.
   Google Scholar
• Calcagno A, Simiele M, Alberione MC, et al. (2015). Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. Clin Infect Dis 60:311–7.
   PubMed Web of Science ®Google Scholar
• Croteau D, Letendre S, Best BM, CHARTER Group, et al. (2010). Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Ch 54:5156–60.
   PubMed Web of Science ®Google Scholar
• Czerniak R. (2001). Gender-based differences in pharmacokinetics in laboratory animal models. Int J Toxicol 20:161–3.
   PubMed Web of Science ®Google Scholar
• Denton PW, Garcia JV. (2009). Novel humanized murine models for HIV research. Curr HIV/AIDS Reports 6:13–9.
   PubMedGoogle Scholar
• Denton PW, Krisko JF, Powell DA, et al. (2010). Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE 5. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0008829 [last accessed 18 Sep 2018].
   PubMed Web of Science ®Google Scholar
• Edén A, Fuchs D, Hagberg L, et al. (2010). HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 202:1819–25.
   PubMed Web of Science ®Google Scholar
• Farhadian S, Patel P, Spudich S. (2017). Neurological complications of HIV infection. Curr Infect Dis Rep 19:50. Available from: https://doi.org/10.1007/s11908-017-0606-5 [Epub ahead of print] [last accessed 19 Sep 2018]
   PubMed Web of Science ®Google Scholar
• Griffin L, Annaert P, Brouwer KL. (2011). Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 100:3636–54.
   PubMed Web of Science ®Google Scholar
• Hassounah SA, Mesplède T, Quashie PK, et al. (2014). Effect of HIV-1 Integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol 88:9683–92.
   PubMed Web of Science ®Google Scholar
• Hatziioannou T, Evans DT. (2012). Animal models for HIV/AIDS research. Nat Rev Microbiol 10:852–67.
   PubMed Web of Science ®Google Scholar
• Hoefnagel JG, Koopmans PP, Burger DM, et al. (2005). Role of the inhibitory quotient in HIV therapy. Anti Ther 10:879–92.
   Google Scholar
• Ito K, Uchida Y, Ohtsuki S, et al. (2011). Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 100:3939–50.
   PubMed Web of Science ®Google Scholar
• Joseph SB, Arrildt KT, Sturdevant CB, Swanstrom R. (2014). HIV-1 target cells in the CNS. J Neurovirol 21:276–89.
   PubMed Web of Science ®Google Scholar
• Letendre S. (2011). Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Topics Antiviral Med 19:137–42.
   PubMedGoogle Scholar
• Liu X, Smith BJ, Chen C, et al. (2006). Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab. Dispos 34:1443–7.
   PubMed Web of Science ®Google Scholar
• MacArthur RD, Novak RM. (2008). Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47:236–41.
   PubMed Web of Science ®Google Scholar
• Marra CM. (2015). HIV-associated neurocognitive disorders and central nervous system drug penetration: what next? Antiviral Ther 20:365–7.
   PubMed Web of Science ®Google Scholar
• Martina T. (2013). Atazanavir causing CNS toxicity? Unexplained neurological symptoms in two patients recently started on atazanavir. J AIDS Clin Res 4:1–2. doi: 10.4172/2155-6113.1000196. Available from: https://www.omicsonline.org/atazanavir-causing-cns-toxicity-unexplained-neurological-symptoms-in-two-patients-recently-started-on-atazanavir-2155-6113.1000196.php?aid=12234 [Accessed 19 September 2018]
   Google Scholar
• Mast N, Li Y, Linger M, et al. (2014). Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice. J Biol Chem 289:3529–38.
   PubMed Web of Science ®Google Scholar
• Mathez D, Schinazi RF, Liotta DC, Leibowitch J. (1993). Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Ch 37:2206–11.
   PubMed Web of Science ®Google Scholar
• Mukerji SS, Misra V, Lorenz DR, et al. (2018). Impact of antiretroviral regimens on CSF viral escape in a prospective multicohort study of ART-experienced HIV-1 infected adults in the United States. Clin Infect Dis67:1182–1190. Available from: https://doi.org/10.1093/cid/ciy267 [Epub ahead of print] [last accessed 1 Sep 2018]
   PubMed Web of Science ®Google Scholar
• Neff PC, Ndolo T, Tandon A, et al. (2010). Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS ONE 5. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015257 [last accessed 1 May 2018]
   Web of Science ®Google Scholar
• New DR, Maggirwar SB, Epstein LG, et al. (1998). HIV-1 Tat induces neuronal death via tumor necrosis factor-α and activation of non-N-methyl-D-aspartate receptors by a NFκB-independent mechanism. J Biol Chem 273:17852–8.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Rossi S, Croteau D, CHARTER Group, et al. (2013). Etravirine in CSF is highly protein bound. J Antimicrob Ch 68:1161–8.
   PubMed Web of Science ®Google Scholar
• Nicol M, Taylor J, Pastick K, et al. (2018). Differential brain tissue penetration of antiretrovirals and fluconazole. In Conference on Retroviruses and Opportunistic Infections (CROI). 4-7 March, 2018. Boston, Massachusetts. Abstract Number: 474. Available from: https://www.croiconference.org/sessions/differential-brain-tissue-penetration-antiretrovirals-and-fluconazole [last accessed 10 Aug 2018]
   Google Scholar
• North TW, Higgins J, Deere JD, et al. (2010). Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84:2913–22.
   PubMed Web of Science ®Google Scholar
• North TW, Van Rompay KK, Higgins J, et al. (2005). Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus Type 1. J Virol 79:7349–54.
   PubMed Web of Science ®Google Scholar
• Pal R, Galmin L, Pereira LE, et al. (2012). Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1. Virology 432:173–83.
   PubMed Web of Science ®Google Scholar
• Rambeck B, Jürgens UH, May TW, et al. (2006). Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 47:681–94.
   PubMed Web of Science ®Google Scholar
• Robertson K, Liner J, Meeker RB. (2012). Antiretroviral neurotoxicity. J Neurovirol 18:388–99.
   PubMed Web of Science ®Google Scholar
• Robichaud G, Garrard KP, Barry JA, Muddiman DC. (2013). MSiReader: an open-source interface to view and analyze high resolving power MS imaging files on matlab platform. J Am Soc Mass Spectr 24:718–21.
   PubMed Web of Science ®Google Scholar
• Shen DD, Artru AA, Adkison KK. (2004). Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Delivery Rev 56:1825–57.
   PubMed Web of Science ®Google Scholar
• Shytaj IL, Norelli S, Chirullo B, et al. (2012). A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathogens 8. Available from: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002774 [last accessed 1 Sep 2018].
   PubMed Web of Science ®Google Scholar
• Smith DA, Di L, Kerns EH. (2010). The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929–39.
   PubMed Web of Science ®Google Scholar
• Srinivas N, Maffuid K, Kashuba ADM. (2018). Clinical pharmacokinetics and pharmacodynamics of drugs in the central nervous system. Clin Pharm 57:1059–74.
   Google Scholar
• Strazielle N, Ghersi-Egea JF. (2015). Efflux transporters in blood-brain interfaces of the developing brain. Front Neurosci. 9:1–11. Available from: https://doi.org/10.3389/fnins.2015.00021 [last accessed 7 Oct 2018].
   PubMed Web of Science ®Google Scholar
• Thompson CG, Bokhart MT, Sykes C, et al. (2015). Mass spectrometry imaging reveals heterogeneous efavirenz distribution within putative HIV reservoirs. Antimicrob Agents Ch 59:2944–8.
   PubMed Web of Science ®Google Scholar
• Thompson CG, Fallon JK, Mathews M, et al. (2017). Multimodal analysis of drug transporter expression in gastrointestinal tissue. AIDS 31:1669–78.
   PubMed Web of Science ®Google Scholar
• Valcour V, Chalermchai T, Sailasuta N, RV254/SEARCH 010 Study Group, et al. (2012). Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 206:275–82.
   PubMed Web of Science ®Google Scholar
• Van Rompay KK, Cherrington JM, Marthas ML, et al. (1996). 9-[2-(Phosphonomethoxy) propyl] adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Ch 40:2586–91.
   PubMed Web of Science ®Google Scholar
• Weiss J, Rose J, Storch CH, et al. (2007). Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Ch 59:238–45.
   PubMed Web of Science ®Google Scholar
• Wijnholds J, deLange EC, Scheffer GL, et al. (2000). Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 105:279–85.
   PubMed Web of Science ®Google Scholar
• Winston A, Khoo S. (2008). Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy? Curr Opinion HIV AIDS 3:608–11.
   PubMed Web of Science ®Google Scholar
• Witvrouw M, Pannecouque C, Switzer WM, et al. (2004). Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Ther 9:57–65.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Price RW, Gisslén M. (2012). Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Ch 67:299–311.
   PubMed Web of Science ®Google Scholar
• Zayyad Z, Spudich S. (2015). Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Current HIV/AIDS Rep 12:16–24.
   PubMed Web of Science ®Google Scholar